High-density lipoprotein cholesterol (HDL-C) has been identified as a powerful independent negative predictor of cardiovascular disease. The beneficial effect of HDL is largely attributable to its key role in reverse cholesterol transport, whereby excess cholesterol in the peripheral tissues is transported to the liver, reducing the atherosclerotic burden. However, mounting evidence indicates that HDL also has pleiotropic properties, such as antiinflammatory, anti-oxidative, and vasodilatory properties, which may contribute in reducing the incidence of heart failure. Actually, previous data from clinical and experimental studies have suggested that HDL exerts cardioprotective effects irrespective of the presence/absence of coronary artery disease. This review summarizes the currently available evidence regarding beneficial effects of HDL on the heart beyond its anti-atherogenic property. Understanding the mechanisms of cardiac protection by HDL will provide new insight into the underlying mechanism and therapeutic strategy for heart failure.
Introduction
Heart failure (HF) is the terminal state of all heart diseases and is the leading cause of mortality worldwide. According to the American Heart Association, there are approximately 550,000 new patients with HF each year 1) . Although considerable advances have been made in our understanding of HF, the incidence, prevalence, mortality, and financial burden of the disease continue to steadily increase in the aging population. Therefore, elucidating modifiable risk factors for HF will aid in identifying prevention strategies or developing novel therapeutic approaches.
Numerous studies have established an inverse relationship between high-density lipoprotein cholesterol (HDL-C) and risk for atherosclerotic cardiovascular disease in humans [2] [3] [4] [5] ; low HDL-C is considered to be one of the most important coronary risk factors 6) . This beneficial effect of HDL on the cardiovascular system is largely attributable to its key role in reverse cholesterol transport (RCT), whereby excessive cholesterol in high toxicity. Myocardium uptakes NEFA as an energy source by passive diffusion and several transporters, such as FA-binding protein, FA translocase (FAT/CD36), and FA transport protein 16) . Hauton et al. investigated myocardial lipid substrate preference by comparing utilization of NEFA, VLDL-TGs, and CM-TGs in rat-isolated perfused hearts and concluded that myocardial utilization of NEFA and CM-TGs is higher than that of VLDL-TGs 21) . Besides LPL-mediated lipolysis, there is an alternative mechanism by which TRL is assimilated into the heart. The VLDL receptor is a member of the LDL receptor gene family, which has high expression in the heart, and is associated with the uptake of apolipoprotein E-containing lipoproteins 22, 23) . Although cardiomyocytes also express scavenger receptor class B type (SR-BI), a receptor related to the uptake of cholesterol from HDL 24, 25) , it remains unknown whether HDL particles are incorporated into the heart via SR-BI.
Cardiomyocytes possess endothelial lipase (EL), which is another member of the TG lipase family. Although basal expression of EL in cardiomyocytes is very low, its expression level is upregulated under pathological conditions, including inflammation, mechanical, and oxidative stress 26) . EL is considered to bind to cell surface proteoglycans where it can directly interact with lipoproteins [27] [28] [29] . EL primarily has phospholipase activity and relatively less TG lipase activity and exhibits preferential substrate specificity for phospholipids on HDL 29) . Therefore, EL has the potential ability to release FAs from not only TGs contained in TRL but also phospholipids contained in HDL. However, relative contribution of EL-mediated HDL hydrolysis and TRL lipolysis in FA supply to the myocardium needs to be determined in the future.
A large amount of evidence suggests that cardiac energy metabolism is severely impaired in the failing heart 30, 31) . Namely, the failing heart is commonly described as an energy-starved engine that has run out of fuel 31) . During development of HF, the predominant myocardial energy substrate switches from FAs to glucose because glucose oxidation allows the heart to produce intracellular adenosine triphosphate (ATP) using less oxygen than that needed for FA oxidation [31] [32] [33] . However, compromised cardiac energy metabolism may cause and worsen myocardial dysfunction. Total -oxidation in the heart is increased by 40% in response to acute energy demand 34) and increased glucose oxidation alone is reported to be insufficient to meet the cardiac energy requirement under stress conditions 33, 35) . Augustus et al. reported that heart-specific LPL knockout (hLpL0) mice were susceptible to HF because of loss of LPL-mediated TG lipolysis in spite of increased glucose oxidation 35) . They showed that hearts of hLpL0 mice that underwent abdominal aortic constriction were dictor of LV mass and LV diastolic dysfunction 11) . An independent association between low HDL-C level and subclinical LV systolic dysfunction has been observed in patients with not only stable angina but also normal coronary angiogram 12) , and Kerola et al. suggested that HDL is superior to B-type natriuretic peptide as a marker of systolic cardiac dysfunction in an elderly general population 13) . Moreover, NIPPON DATA90, a large cohort study of cardiovascular disease in Japan, addressed the association between HDL-C levels and HF incidence; serum HDL-C levels tended to show an inverse association with HF mortality with borderline significance and a significant inverse association with all-cause mortality 14) . In line with this observation, Vredevoe et al. reported that HDL-C is a predictor of mortality in patients with idiopathic HF 15) . Taken together, HDL exerts direct cardioprotective effects independent of the atheroprotective property, which possibly influences LV function and HF incidence. In the present review, we summarize currently available evidence regarding direct beneficial effects of HDL on the heart beyond the anti-atherogenic property and discuss underlying mechanisms that have been implicated.
HDL Provides Fatty Acids as Energy Substrates for the Myocardium
Vast amounts of energy are required for fueling the continuous pumping action of the heart. Under normal circumstances, nearly 70% of the energy substrate used for myocardial contraction is derived from fatty acid (FA) oxidation and the remainder comes from glucose, lactate, and ketone body oxidation 16) . Thus, FAs are considered to be the major energy source for the myocardium, which are delivered to cardiomyocytes in three ways: 1) FAs are produced in the local capillary bed by hydrolysis of triglycerides (TGs) contained in circulating TG-rich lipoproteins (TRL), such as chylomicrons and very low-density lipoproteins (VLDL), via actions of lipoprotein lipase (LPL), 2) FAs are produced by hydrolysis of intracellular TG storages, and 3) FAs are derived from circulating free FAs, referred to as nonesterified FA (NEFA), complexed with serum albumin 17) . Moreover, phospholipids might be one of the resources of FAs, whereas metabolic regulation in the heart remains to be fully elucidated. In particular, LPLmediated lipolysis of chylomicrons and VLDL significantly contributes to cardiac energy supply 18, 19) ; therefore, LPL plays a central role in energy homeostasis in the heart 17) . LPL is synthesized in cardiomyocytes and then migrates to the luminal surface of vascular endothelial cells where hydrolysis of TRL takes place 20) . In contrast to esterified FAs derived from TRL, NEFA availability is limited because of its low solubility and emia-reperfusion (I/R) injury, Marchesi M et al. showed that synthetic HDL, recombinant apo A-I Milano complexed with 1-palmitoyl-2-oleoyl phosphatidylcholine, reduced cardiac muscle lipid hydroperoxide levels by 46% via its antioxidant potential, thereby attenuating post-ischemic LV dysfunction 44) . We recently reported that HDL treatment improved cardiomyocyte viability under oxidative stress through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway 45) . mTOR belongs to the PI3K-related kinase family and critically regulates protein synthesis, cell survival, growth, and proliferation 46) . In addition, several studies have identified mTOR as an important regulator of cardiac adaptation because its overexpression is protective in pressure-overloaded mouse hearts 47, 48) and its conditional knockout in murine heart causes cardiac dysfunction 49) . We demonstrated that HDL activated downstream effectors of mTOR signaling, which played anti-apoptotic roles under oxidative stress, may contribute to cardioprotection 45) .
HDL Exerts Anti-Inflammatory Effects in the Myocardium
HF is known as a disorder characterized in part by immune activation and inflammation 50) . Niebauer et al. showed that plasma bacterial endotoxin (lipopolysaccharide, LPS) levels were increased in patients with HF and peripheral edema probably because venous congestion leads to altered gut permeability for endotoxin and translocation of the endotoxin into the systemic circulation 51) . Because endotoxin is a very strong stimulator for the release of inflammatory cytokines from circulating immune competent cells 52) , it may cause substantial immune activation in patients with HF. Conversely, lipoproteins have been shown to bind and inactivate endotoxin in proportion to their cholesterol content 53) . It has been postulated that low plasma cholesterol levels, a surrogate for the totality of lipoproteins, is related to impaired survival in patients with idiopathic HF 15) . Similarly, Rauchhaus M et al. proposed that high plasma cholesterol levels in chronic HF are beneficial on the basis of the capacity of circulating cholesterol-rich lipoproteins to bind and inactivate endotoxin 52) . Notably, Ulevitch et al. reported that HDL suppressed the buoyant density of LPS in human serum more effectively than LDL or VLDL 54) . Similar to this finding, it was reported that the phospholipid bilayer of the HDL surface could bind to lipid-A, an anchor protein of LPS, to neutralize the activity of LPS 55) . In fact, HDL inhibits LPS-induced expression of cytokines in cardiomyocytes (Fig. 1A) . In addition, infusion of reconstituted HDL reduces cytokinemia and unable to adapt acutely to pressure overload, thereby, all banded hLpL0 mice died within 48 h, whereas all banded wild-type mice continued to thrive. Similarly, the lack of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1 ), a regulator of numerous genes involved in FA import and oxidation, accelerates pressure overload-induced HF induced by transverse aortic constriction 36) . These findings indicate that FAs are indispensable energy substrates even in the failing myocardium.
Kratky et al. observed that EL compensates for free FA uptake in LPL-deficient mouse adipose tissue, which indicates that EL provides an alternative pathway for FA uptake when the action of LPL is insufficient 37) . Expression of EL in the cardiac tissues is increased in the early phase of pressure overload-induced HF, whereas expression of LPL is significantly decreased 26) . Subsequently, EL deficiency worsens pressure overload-induced HF due to the attenuated energy production from FA oxidation, which suggests that EL-mediated FA supply from HDL is important for the myocardium in the setting of increased energy demand or insufficient LPL action. In addition, various FAs act as ligands for PPAR 38) , which regulates mitochondrial FA oxidation-related genes. Ahmed et al. revealed that ELmediated hydrolysis of HDL activates PPAR and subsequently upregulates the expression of acyl-CoA-oxidase, a well-established FA oxidation-related gene 39) . In line with this finding, incubation of EL-overexpressing cardiomyocytes with HDL augmented the expression of FA oxidation-related genes carnitine palmitoyltransferase-1 and medium-chain acyl CoA dehydrogenase which was accompanied by an increase in intracellular ATP 26) . From these findings, it is considered that ELmediated FA supply from HDL not only increases energy substrates for the myocardium but also upregulates the expression of PPAR -mediated FA oxidationrelated genes, thereby preserving FA utilization in the failing heart.
HDL Protects Cardiomyocytes Against Oxidative Stress
There is a well-established relationship between myocardial reactive oxygen species (ROS) levels and left ventricular contractile dysfunction, which results in HF 40, 41) . ROS is generated in the ischemic myocardium, particularly after reperfusion, leading to cell death 42) . One of the most important properties of HDL is its ability to reduce oxidative stress caused by excessive ROS formation 7, 8) . There is evidence that HDL inhibits NAD(P)H oxidase-dependent ROS generation in vascular smooth muscle cells and isolated aortas 43) . With regard to the myocardium, in an ex vivo model of isch-
HDL Protects Cardiomyocytes by Activating Beneficial Signal Transducers in the Heart
Among HDL constituents that mediate diverse biological effects, S1P is one of the major lipid constituents of HDL; it has gained special attention because it may be responsible for many of the pleiotropic effects of HDL. The major source of S1P is hematopoietic cells (mainly erythrocytes, platelets, and leukocytes), whereas HDL serves as a major carrier of extracellular S1P in the plasma 62) . Zhang et al. showed that HDL-associated S1P is the major determinant of the plasma S1P level and positively correlates with HDL-C and apoliimproves clinical outcome in rabbit gram-negative bacteremia models 56) . Furthermore, targeted deletion of EL results in an increase in phospholipid and cholesterol content in HDL particles and thereby improves the survival rate of endotoxin shock in a mouse model of LPS-induced septic shock 57) . These findings indicate that HDL can diminish detrimental effects of endotoxemia in vivo. Therefore, it is reasonable to assume that HDL protects against HF by attenuating the action of endotoxin in edematous patient with HF.
HDL Enhances Myocardial Perfusion Via Nitric Oxide-Mediated Vasodilatory Effects
There is evidence that HDL administration increases myocardial perfusion in vivo via nitric oxide (NO)-dependent mechanisms 58) , suggesting that HDL acts as a coronary vasodilator. HDL mediates vasodilatation via NO release [59] [60] [61] . Nofer et al. reported that HDL stimulates NO release in human endothelial cells and induces vasodilation in isolated aortas via intracellular Ca 2 mobilization and Akt-mediated endothelial NO synthase (eNOS) phosphorylation 59) . The vasoactive effect of HDL was mimicked by three lysophospholipids contained in HDL: sphingosine-1-phosphate (S1P), sphingosylphosphorylcholine (SPC), and lysosulfatide (LSF). Deficiency of the S1P3 receptor abolished vasodilatory effects of these lysophospholipids, which indicates that HDL functions as a carrier of bioactive lysophospholipids and induces NO-dependent vasodilation via S1P3 receptor. Conversely, Yuhanna et al. have shown that HDL activates eNOS via SR-BI through a process that requires apoA-I binding in endothelial cells, resulting in increased NO production 60) . Afterward, it was identified that apoA-I interaction with SR-BI led to Src-mediated PI3K activation and then PI3K activated Akt kinase and mitogen-activated protein kinase pathways, both of which stimulate eNOS activity 61) . Collectively, HDL activates eNOS in endothelial cells through dual signaling pathways involved in S1P receptors and SR-BI and causes NO-mediated vasodilation. In the heart, Levkau B et al. observed that administration of human HDL enhanced incorporation of the perfusion tracer 99mTc-methoxyisobutylisonitrile into the murine heart in vivo by approximately 18%; this increase was completely abolished in mice deficient of endothelial NO synthase 58) . Furthermore, the stimulatory effect of HDL on myocardial perfusion was preserved in S1P3-deficient mice, which implies that SR-BI-mediated, but not S1P3-mediated, eNOS activation in endothelial cells may be mainly related to the stimulatory effect of HDL on myocardial perfusion. We found that HDL protects the cardiomyocytes from cell death (Fig. 1B) . In addition, we have revealed that HDL treatment improves cardiomyocyte viability under oxidative stress and that the PI3K/mTOR signaling pathway mediates these effects 45) . In this study, we demonstrated that HDL treatment increased phosphorylation of the ribosomal protein S6 kinase (S6K) and BCL2-associated agonist of cell death (BAD) under oxidative stress via PI3K/mTOR. S6K is known as a downstream effector kinase of mTOR signaling and is related to anti-apoptotic signaling through maintenance of BAD phosphorylation. Shende et al. reported that mTOR-complex 1 activity was essential for preserving cardiac function. Its deletion impaired cardiac function, leading to dilated cardiomyopathy and high mortality 74) . Correspondingly, they showed that the mTORcomplex 2 was associated with preserving left ventricular contractile function of pressure-overloaded mouse hearts. Cardiac dysfunction due to transverse aortic constriction was more severe after ablation of rictor, a specific component of mTOR2 75) . Thus, in terms of cardiac protection, HDL could be an important activator of mTOR signaling.
Conclusion
Increasing evidence in clinical and in experimental studies has underlined that HDL exerts many beneficial effects in addition to anti-atherogenic effects on the heart. Given that HF usually develops gradually on the basis of multifactorial disorders, including vascular, myocardial, and metabolic disorders, pleiotropic properties of HDL potentially help in maintaining normal cardiac function (Fig. 2) . HDL may protect the myocardium by functioning as an energy fuel, NOmediated vasodilator, and signaling molecule and by promoting anti-inflammatory and anti-oxidative effects. Although recent clinical trials using cholesteryl ester transfer protein (CETP) inhibitors 76) or niacin 77) did not verify the beneficial effects of HDL-C increasing therapy, the primary outcome in these studies largely seems to depend on the onset of atherosclerotic vascular diseases. Conversely, it has been shown that pharmacological modification of HDL phospholipids can improve HDL functions 78, 79) . A better understanding of the direct cardioprotective effects of HDL needs to be determined in humans for seeking novel therapeutic strategies of HF.
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